Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Cara Therapeutics, Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutics employs 72 staff and has a trailing 12-month revenue of around USD$24 million.
Since the stock market crash in March caused by coronavirus, Cara Therapeutics's share price has had significant negative movement.
Its last market close was USD$13.73, which is 20.31% down on its pre-crash value of USD$17.23 and 54.62% up on the lowest point reached during the March crash when the shares fell as low as USD$8.88.
If you had bought USD$1,000 worth of Cara Therapeutics shares at the start of February 2020, those shares would have been worth USD$678.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$841.79.
|Latest market close||USD$13.73|
|52-week range||USD$8.88 - USD$26.67|
|50-day moving average||USD$15.9585|
|200-day moving average||USD$15.4238|
|Wall St. target price||USD$33.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.166|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-14)||-11.42%|
|1 month (2020-08-24)||-10.96%|
|3 months (2020-06-20)||N/A|
|6 months (2020-03-23)||24.14%|
|1 year (2019-09-20)||-38.04%|
|2 years (2018-09-21)||-40.77%|
|3 years (2017-09-21)||4.17%|
|5 years (2015-09-21)||-34.34%|
|Revenue TTM||USD$24 million|
|Gross profit TTM||USD$-93,934,000|
|Return on assets TTM||-47.25%|
|Return on equity TTM||-96.01%|
|Market capitalisation||USD$681.3 million|
TTM: trailing 12 months
There are currently 4.0 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 11.9% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.
Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 364972.61146497). Cara Therapeutics's SIR currently stands at 10.99. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 10990 shares are currently held short.
However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0914% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 91 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cara Therapeutics.
Find out more about how you can short Cara Therapeutics stock.
We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.
Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.
Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $8.88 up to $26.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.7012. This would suggest that Cara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.